{"count": 2, "results": [{"_id": "38291943", "pmid": 38291943, "title": "Association of metformin use and cancer incidence: a systematic review and meta-analysis.", "journal": "J Natl Cancer Inst", "authors": ["O'connor L", "Bailey-Whyte M", "Bhattacharya M", "Buttera G", "Hardell KNL", "Seidenberg AB", "Castle PE", "Loomans-Kropp HA"], "date": "2024-01-30T00:00:00Z", "doi": "10.1093/jnci/djae021", "meta_date_publication": "2024 Jan 30", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50249.363, "text_hl": "Reduced risk for overall @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ was observed in case-control (RR, 0.55; 95% CI, 0.30-0.80) and prospective cohort (RR, 0.65; 95% CI, 0.37-0.93) studies. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ use was associated with reduced @DISEASE_Gastrointestinal_Diseases @DISEASE_MESH:D005767 @@@gastrointestinal@@@ (RR, 0.79; 95%CI, 0.73-0.85), @<m>DISEASE_Urologic_Diseases</m> @DISEASE_MESH:D014570 @@@urologic@@@ (RR, 0.88; 95%CI, 0.78-0.99), and @DISEASE_Hematologic_Diseases @DISEASE_MESH:D006402 @@@hematologic@@@ (RR, 0.87; 95%CI, 0.75-0.99) @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ risk. ", "citations": {"NLM": "O'connor L, Bailey-Whyte M, Bhattacharya M, Buttera G, Hardell KNL, Seidenberg AB, Castle PE, Loomans-Kropp HA. Association of metformin use and cancer incidence: a systematic review and meta-analysis. J Natl Cancer Inst. 2024 Jan 30;():. PMID: 38291943", "BibTeX": "@article{38291943, title={Association of metformin use and cancer incidence: a systematic review and meta-analysis.}, author={O'connor L and Bailey-Whyte M and Bhattacharya M and Buttera G and Hardell KNL and Seidenberg AB and Castle PE and Loomans-Kropp HA}, journal={J Natl Cancer Inst}}"}}, {"_id": "29117997", "pmid": 29117997, "title": "Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?", "journal": "Am J Physiol Renal Physiol", "authors": ["Wang Z", "Olumi AF"], "date": "2018-03-01T00:00:00Z", "doi": "10.1152/ajprenal.00443.2017", "meta_date_publication": "2018 Mar 1", "meta_volume": "314", "meta_issue": "3", "meta_pages": "F407-F411", "score": 50056.613, "text_hl": "In this perspective, we provide our findings and understanding of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ as an alternative way to treat @<m>DISEASE_Urologic_Diseases</m> @DISEASE_MESH:D014570 @@@urological abnormal proliferation@@@. ", "citations": {"NLM": "Wang Z, Olumi AF. Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F407-F411. PMID: 29117997", "BibTeX": "@article{29117997, title={Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?}, author={Wang Z and Olumi AF}, journal={Am J Physiol Renal Physiol}, volume={314}, number={3}, pages={F407-F411}}"}}]}